- ValiRx said an independent analysis of data showed a statistically significant response in a treatment trial involving patients with hormone-sensitive and hormone-resistant prostate cancer.

The results came from an initial formal statistical analysis of clinical data for the treatment, VAL201, conducted by independent statistical consultant Wilson Caparros-Wanderley.

Volunteers treated with VAL201 were found to display a statistically significant correlation for reductions over time in the amount of testosterone and prostate specific antigen, both of which are commonly-used markers for disease progression in prostate cancer.

The data further confirmed no statistically significant adverse trends across liver or kidney function.

At 8:14am: [LON:VAL] ValiRx PLC share price was +0.25p at 1.45p

Story provided by